Caribou Biosciences

CRBUNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$139.370 M

$1.30 +0.00%

Close of 21 Sept 2026

Revenue

$11.2M

#3130 by revenue

Earnings

-$148.1M

Loss-making

Shares outstanding

107,207,513

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#106Tenaya TherapeuticsTNYA$151.1M
#107Molecular PartnersMOLN$149.7M
#108Caribou BiosciencesCRBU$139.4M
#109enGene TherapeuticsENGN$131.4M
#110Neumora TherapeuticsNMRA$130.0M

What if Caribou Biosciences were worth as much as…

Open the what-if tool →

Gold $30.3T

$282,387.43

Per share 217,221× higher

Bitcoin $1.72T

$16,041.82

Per share 12,340× higher

Nvidia $5.48T

$51,114.50

Per share 39,319× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Caribou Biosciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.